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G ra n u lo cy te -M a cro p h a g e  C olony-Stim ulating  Factor  
A sso c ia te d  W ith Induction  Treatm ent o f  A cute  
M y e lo g e n o u s  Leukem ia: A Random ized T ria l by the  
E u r o p e a n  O rgan iza t ion  for Research and T reatm ent o f
C a n cer  Leukem ia Cooperative G roup
By Robert Zittoun, Stefan Suciu, Franco Mandelli, Theo de Witte, Josef Thaler; Pierre Stryckmans, Marcel Hayat,
Marc Peetermans, Monique Cadiou, Gabriel Solbu, Maria Concetta Petti/ and Roel Willemze
Purpose: To assess the value o f granulocyte-macro­
phage colony-stim ulating factor (GM-CSF) for induction 
treatm ent of acute m yeloid leukem ia (AML)/ both for prim­
ing o f leukemic cells and fo r acceleration o f hematopoietic 
recovery*
Patients and Methods: GM-CSF was administered 5 fj, g / 
k g /d  by continuous intravenous (IV) infusion during induc­
tion therapy w ith  daunorubicin (DNR) (days 1 to 3) and 
cytarabine (ARA-C) (days 1 to 7). A  total o f 102 patients 
were random ized onto four arms, as follows: (1) GM-CSF 
24 hours before and during chemotherapy (arm + / — ); (2) 
GM-CSF after chem otherapy until day 28 or recovery of 
polym orphonuclear leukocytes (PMNs) (arm - /+ ) ;  (3) GM- 
CSF before, during, and a fter chemotherapy (arm + /+ ) ; or 
(4) no GM-CSF (arm Stopping rules were applied in
case o f an in itia l WBC count greater than 30 x 109/L  or a 
secondary increase o f circulating blast cells. Analyses were 
perform ed according to  the intention-to-treat principle.
He m a t o po ie t ic  g r o w t h  factors <hgfs), espe­cially granulocyte colony-stimulating factor (G- 
CSF) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) are currently used in cancer chemother­
apy to accelerate the recovery of hematopoiesis, although 
their real impact in terms of cost-effectiveness is still 
debated. They are also increasingly used for mobilization 
of peripheral-biood progenitor cells in view of autologous 
transplantation.
In acute myeioid leukemia (AML), leukemic blast ceils 
express receptors for HGFs, with interindividual variabil­
ity in number, type, and affinity of receptors.1 Treatment
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Results: The complete remission (CR) rates were 77% 
(arm — / — )7 72% (arm + / - ) ,  48% (arm - / + ) ,  and 46% 
(arm + /+ ). Patients randomized to receive GM-CSF after 
induction (arms - / +  and + / + )  had a significantly lower 
CR rate (P = .008) and a trend tow ard accelerated recovery 
of neutrophils, but no fewer infections or induction deaths. 
The lower CR rate appeared to be related to an increased 
resistance rate, w ith persistent leukemia. The main side ef­
fects of GM-CSF were fluid retention and hypotension.
Conclusion: GM-CSF administered during induction 
treatment of AML w ith a DNR/Ara-C combination did not 
provide any clinical benefit. Furthermore, there was a sig­
nificant decrease in the CR rate w ith  more persistent leuke­
mia when GM-CSF was administered during the hypoplas­
tic phase after the chemotherapy courses.
J Clin Oncol 14:2750-2159. © 1996 by American So­
ciety of Clinical Oncology.
of AML with HGFs theoretically has two types of poten­
tial therapeutic effects as follows: (1 ) they can recruit 
leukemic cells into cycle and thus enhance their sensitiv­
ity to chemotherapy2,3; therefore, their administration be­
fore and during chemotherapy could lead to increased 
leukemic cell kill. (2) when administered after cytotoxic 
courses, they can stimulate normal hematopoietic progen­
itors and thus accelerate hematopoietic recovery and re­
duce the morbidity and eventual mortality from infection.
The presence of receptors for HGFs in both normal 
and leukemic cells could challenge these therapeutic ef­
fects by two possible adverse consequences: (1) when 
given before and during chemotherapy, recruitment of 
normal pluripotent stem cells in cycle may increase the 
fraction exposed to cycle-dependent cytotoxic drugs and 
result in more prolonged marrow aplasia; (2) when ad­
ministered after chemotherapy courses, stimulation of re­
sidual leukemic clones may occur, with a risk of resis­
tance to induction treatment or early relapse. Whether 
given during or after induction courses, HGFs might pre­
vent chemotherapy-induced apoptosis of leukemic cells.4,5
Several pilot studies that combined GM-CSF during 
induction treatment of AML have indicated that it could 
result in an higher complete remission (CR) rate when 
compared with historical controls.6'9 These pilot studies 
were followed by prospective randomized trials. In two 
consecutive studies, Ohno et al10,11 have shown that G- 
CSF accelerates the recovery of neutrophils, with a trend
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for less documented infections, while the CR rate was 
not significantly increased.
Results of other cooperative trials that used GM-CSF 
or G-CSF have been recently published.12"16 Unfortu­
nately, the designs vary among studies, which makes 
comparisons difficult. In addition, no attempts were made 
to assess separately the two possible biologic effects: the 
priming effect by administration before and during che­
motherapy courses, and the acceleration of normal hema­
topoietic recovery by postchemotherapy administration. 
The European Organization for Research and Treatment 
of Cancer (EORTC) Leukemia Cooperative Group has 
decided to study prospectively the value of these two 
types of administration of GM-CSF during the induction 
phase in previously untreated AML patients.
PATIENTS AND METHODS
The present trial (GM-CSF amendment) was designed as an exten­
sion of a large randomized study, AML 8, of the EORTC and Gruppo 
Italiano Malattie Ematologiche Maligne dell’ Adulto (GIMEMA) 
Leukemia Cooperative Groups. In this study, newly diagnosed pa­
tients aged 15 to 45 years were eligible for AML 8A, which com­
pared the following three post-CR strategies: allogeneic bone mar­
row transplantation (BMT), autologous BMT, and short intensive 
chemotherapy consolidation. The results of the AML 8A study* not 
including the amendment with GM-CSF, have been recently pub­
lished.17 Patients aged 46 to 60 years, in the meantime, were entered 
onto the AML 8B protocol, which compared the same intensive 
chemotherapy consolidation and standard postremission regimens of 
the EORTC and GIMEMA groups. The induction course used in 
these two trials consisted of a combination of daunorubicin (DNR) 
and cytarabine (ARA-C), and was repeated once if a partial remission 
(PR) was reached by day 28. Response to induction treatment was 
classified as CR if there were ^ 5 %  bone marrow blast cells with 
a normal blood count, PR if there were near normal blood counts 
and 6% to 25% bone marrow blasts, early death if death occurred 
before completion of the first induction course, death during hypo­
plasia, and resistant disease if there was persistent disease in surviv­
ing patients.
Patients
In the present GM-CSF amendment protocol, patients were treated 
exactly as in the main study AML BA or SB, except for the random­
ization of GM-CSF during the induction phase. Only a limited num­
ber of pilot centers were allowed to participate in this amendment, 
by enrolling all of their patients consecutively hospitalized for AML, 
whereas the other centers continued to treat patients according to 
the main protocols. Selection criteria were almost the same as in the 
main studies. All patients aged 15 to 60 years with previously un­
treated AML were eligible on the basis of morphology criteria ac­
cording to the French-American-British (FAB) classification.18 Pa­
tients with blast crisis of chronic myeloid leukemia, AML that 
supervened after other myeloproliferative diseases, or after a myelo- 
dysplastic syndrome of more than 6 months’ duration were excluded, 
as were patients with a severe concomitant disease or coexistent 
and progressive malignancy. However, contrary to the main study, 
patients with a poor performance status (World Health Organization 
[WHO] score > 2) or serum creatinine concentration greater than 1.5 
times the upper limit of normal were excluded from the amendment. 
Informed consent was required before randomization, according to 
local rules. All smears were centrally reviewed for eligibility at 
diagnosis and for response.
Treatment Protocol
The design of the treatment protocol is shown in Fig 1. Patients 
received induction chemotherapy treatment that combined DNR 45 
mg/m2/d by intravenous (IV) push on days 1 to 3 and Ara-C 200 
mg/nr7d by continuons IV infusion on days 1 to 7 and were random­
ized to one of the four following arms: (1) control arm without 
GM-CSF (-/-); (2) GM-CSF starting 24 hours before induction 
chemotherapy and continuing until completion of the chemotherapy 
course on day 7 (+/—); (3) GM-CSF started immediately after com­
pletion of the chemotherapy induction course on day 8 and continu­
ing until day 28» or for a shorter time in case of earlier neutrophil 
recovery with a polymorphonuclear leukocyte (PMN) count ^0 .5  
X 10lJ/L (—/+); or (4) GM-CSF started 24 hours before the chemo­
therapy induction course and continuing until day 28 or a PMN 
count 0.5 X Ï09/L (+/-H). Patients who did not achieve a CR 
after one course, but met criteria that corresponded to a PR on day
28, received a second identical induction course, with GM-CSF 
administered or not according to randomization arm. GM-CSF was 
provided by Sandoz/Schering Plough (Basel, Switzerland) as recom­
binant human Escherichia coli-derived sterile lyophilized powder. 
It was reconstituted with sterile water, diluted with 0.9% sodium 
chloride to a maximum 50 mL total volume, and administered by 
continuous IV infusion through a central vein catheter at a daily 
dose of 5 ^g/kg. According to the protocol, administration of GM- 
CSF was delayed in patients randomized to arms 2 and 4 in case of 
an initial blast count greater than 30 X 10‘VL, and was subsequently
DNR % 0 O
Fig 1. Protocol design. DNR 
45 mg/m2/d on days 1 to 3, Ara- 
C 200 mg/m2/d by continous IV 
infusion on days 1 to 7. GM-CSF 
5 f z g j kg/d by continous IV infu­
sion. GM-CSF delayed if circulat­
ing blast count > 30 x 109/L, 
started when <  20; Interrupted 
if, after chemotherapy, blasts 
are no longer seen and subse­
quently are > 1 x 109/L or per­
sist and increase twofold.
ARA-C
GM-CSF
+ /-
-  /+
+ / +
Day
N o  G M - C S F
0 1 2 3 4 5 6 7 8 •  *  i 28
(or PMN > 0.5)
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started, after initiation of chemotherapy, when the circulating blast 
count decreased to less than 20 X 10y/L. GM-CSF was also discon­
tinued during chemotherapy if the blast count increased to 50 X 10*7 
L, and was reintroduced when the count decreased to less than 20 
X 109/L. In addition, after the end of the chemotherapy course, GM- 
CSF was stopped if the circulating blast cells were not or no longer 
detectable and subsequently reappeared to values ^  1 X 109/L, or 
if they persisted and then increased by at least twofold. Furthermore, 
GM-CSF was stopped at any time in case of severe side effects, or 
allergic or anaphylactoid reactions. To avoid fluid retention, patients 
received furosemide from the beginning, plus IV infusion of albumin 
in case of marked hypoalbuminemia. Body weight was assessed 
daily; GM-CSF was interrupted in case of weight increase by more 
than 5 kg, and reinitiated only if the body weight decreased by at 
least 3 kg.
No GM-CSF was administered during salvage treatment (combin­
ing mainly inLermediate-dose Ara-C and idarubictn or amsacrine) in 
patients resistant to the induction therapy or during post-CR treat­
ments.
Statistical Methods
Randomization was centrally performed at the EORTC Data Cen­
ter in Brussels using the minimization technique, with age and treat­
ment center being used as stratification factors.
The 2 X 2  factorial design allowed evaluation of two experimental 
groups: ■/+, GM-CSF administered after induction chemotherapy, 
whatever the treatment applied during induction (ie, with or without 
GM-CSF); and +/*, GM-CSF administered before and during in­
duction chemotherapy, whatever the treatment applied after induc­
tion (ie, with or without GM-CSF). These two groups were compared 
with the two corresponding control treatment groups through an a 
posteriori stratification; •/+ to •/—, GM-CSF or not after induction 
chemotherapy, whatever the treatment applied during induction (ie, 
with or without GM-CSF); and +/• to —/*, GM-CSF or not during 
induction chemotherapy, whatever the treatment applied after induc­
tion (ie, with or without GM-CSF), respectively.
In the treatment evaluation, the following end points were used: 
response to the first induction course, response to one or two induc­
tion courses, overall response to induction or salvage treatment, 
event-free survival (EFS) and overall survival. EFS was defined as 
the time from evaluation of induction until relapse or death in CR; 
patients who did not reach CR after induction were considered as 
treatment failures at time 0. Duration of survival was calculated 
from the date of randomization until death, whatever the cause of 
death.
in all analyses, the intention-to-treat principle was used, ie, all 
patients were kept in the treatment arm allocated by randomization. 
All patients have been monitored in the same way, irrespective of 
treatment arm.
The relationship between treatment group and response to chemo­
therapy course (categorized as CR and no CR) was tested for statisti­
cal significance using the x1 test with continuity correction.19 Each 
of the two comparisons (GM-CSF during induction, no v yes; and 
GM-CSF after induction, no v yes) has been adjusted mutually by 
each other. For a 2 X 2 contingency table (treatment v response), 
the odds ratio (OR) and its 95% confidence interval (Cl) was calcu­
lated using the Confidence Interval Analysis program.20 If the lower 
limit of the 95% Cl is greater than 1, then the true OR is (with 95% 
chances) greater than 1, ie, the experimental group has a significant 
adverse impact on the response rate.
The Kaplan-Meier19 method was used to construct EFS and sur­
vival curves. Comparison between the groups for treatment outcome
was tested for statistical significance using the two-sided log-rank 
test. The relative risk of death in the experimental versus the control 
group was estimated via the OR method, along with its 95% Cl.211 
For multivariate analyses with binary outcome, the linear logistic 
model19 was used, and for EFS analysis, Cox’s proportional hazards 
model19 was used.
The initial aim of the study was to randomize 600 patients in 
order to delect an improvement from 65% to 75% in terms of CR 
rate (OR = 0.63, alpha = 0.05, beta = 0.15). Due to the risk of 
yielding worse results in the GM-CSF-containing groups, particu­
larly in the • /+ group, close monitoring of the trial was performed. 
After 103 patients had been recruited onto the trial, and the first 93 
were evaluated for response, it appeared that the estimated OR for 
the comparison •/+ versus •/— was significantly (P = .01) greater 
than 1, and that its corresponding 99.9% Cl did not contain the 
initial targeted value (ie, 0.63). It was therefore decided to stop the 
trial prematurely,
RESULTS
Characteristics of Treatment Arms and Groups
A total of 103 patients from eight centers were included 
from December 1990 to November 1992. All patients 
were eligible for entry onto the study. One patient ran­
domized to the +/+ arm, who had severe complications 
from the central venous access device that allowed only 
palliative chemotherapy without GM-CSF, was not as­
sessable for response. The main characteristics of the 
remaining 102 eligible and assessable patients are listed 
in Table 1. The control group is characterized by slightly 
fewer unfavorable prognostic features, such as WBC 
count greater than 100 X 109/L and fever at diagnosis, 
and more patients with Auer rods present in blast cells. 
Cytogenetics were performed in 58 patients and showed 
an even distribution in the four treatment arms when 
grouped into good, intermediate, and poor prognostic cat­
egories according to Keating’s classification.21
Four patients randomized to the +•/—, -/+, and +/+ 
arms did not receive GM-CSF because of leukostasis, 
vasculitis and lung infiltration, skin vasculitis, and leuke­
mic pleuritis (Table 2). All four patients received the 
chemotherapy according to the AML 8 protocol and were 
kept for analysis in their treatment arm allocated by ran­
domization. Table 2 also lists the number of patients in 
whom the start of GM-CSF was, according to the proto­
col, delayed or prematurely stopped for increased blast 
cells or toxicity. Due to an initial high WBC count, the 
start of GM-CSF was postponed in 20 patients. In five 
patients who received GM-CSF before induction chemo­
therapy (arms +/— and -1-/+), an increased WBC count 
by twofold to 15-fold was observed on day 1 or 2. This 
increase during GM-CSF did not seem to correlate with 
response (three in CR and two with resistance). In addi­
tion, GM-CSF was temporarily interrupted in eight pa­
tients and prematurely stopped in 43. The reasons for 
premature stopping of GM-CSF are also listed in Table
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Table 1. Patient Characteristics at Diagnosis by Treatment Arm
Characteristic
Treatment Arm
-/- (n = 26) +/- In = 25) -/+ (n = 27) +/ + (n — 24)
Age, years
Median 45 45 42 42
Range 26-59 22-58 17-59 2)-55
Sex ratio (male/female) 0.86 1.08 1.08 1.18
Performance status grade 2 v 0 or 1 3 4 3 4
Fever > 38°C at entry 4 8 ó 8
WBC count (X 107L)
30-99 8 7 7 9
ooAl 0 2 2 3
Auer rods positive 12 10 10 9
FAB subfype
M1/M2/M3 2/7/1 4 /9 /2 4 /6 /0 2/7/1
M4/M5/M6/M7 7/8/1 2 /6 /2 7/8 /2 9/4/0/1
Cytogenetic risk group (good/intermediate/poor) 3/9/4 2/6/6 3/7/8 3/4/3
2, The more frequent reasons were early PMN recovery 
(16 patients) and increased circulating blast cells ( 11 pa­
tients), which led to stopping GM-CSF on days 16 to 26 
(median, 22.6) and 11 to 24 (median, 19.3)* respectively. 
The other reasons were side effects assumed to be due 
to GM-CSF (mainly fever, flu-like syndrome, fluid reten­
tion, and cardiac failure), and, in six cases, severe infec­
tion associated with serious clinical problems.
Response to Induction and Salvage Treatments
Response to induction treatment, according to random­
ization, is listed in Table 3. The highest CR rate after the 
first induction course was observed in the control arm. 
The three treatment arms showed a trend for a lower CR 
rate and an increased resistance rate, especially in the two 
arms —/+ and +/-K
The effect of GM-CSF was analyzed by treatment 
group (Table 4) after the first induction course or after 
the whole induction treatment (one or two courses). The 
differences between CR rates of the groups randomized 
to receive or not receive GM-CSF during induction che­
motherapy were not significant, whether one considers 
the results after the first cycle only (51.0% v 60.4%) or 
the overall results (59.2% v 62.3%). In contrast, the CR 
rate was significantly lower for the group randomized to 
receive GM-CSF (group •/+) during the postchemother- 
apy period, compared to the group •/—; 43.1% versus 
68.6% {P = .015) after the first course and 47.1% versus 
74.5% (.P — .008) after one or two courses. These differ­
ences were mainly attributable to an increased resistance 
rate in the group ■/+ compared with */—. On the basis 
of the treatment protocol, administration of GM-CSF was 
delayed in case of an initial WBC count greater than 30 
X  109/L. However the CR rate in the group • / +  was still 
significantly lower than in the group « /— after adjustment 
for WBC count.
If one takes into consideration several factors that may 
influence the CR rate after induction, such as age, sex, 
FAB cytology subtype, fever, WBC count, platelet count, 
performance status, Auer rods, and treatment group, the 
linear logistic model showed that treatment group (•/- 
v * /+) was the most predictive variable (P = .005), fol-
Table 2. Patients in Whom GM-CSF Was Not Given, Delayed, or Prematurely Stopped by Treatment Arm
Variable
Treatment Arm
Total 
IN -  76)
■h/~- {n « 25) —/+ (n = 27} +/+ (n —24)
No. % No. % No. %
GM-CSF not given 1 4 2 7 1 4 4
GM-CSF delayed 9 36 — 11 46 20
GM-CSF prematurely stopped 2 8 21 78 20 83 43
Main reason for interruption
Early PMN recovery 11 41 5 21 16
Increase of blast cells 4 15 7 29 11
Supposed toxicity 2 8 3 11 2 8 7
Cardiac failure 1 4 2 8 3
Severe infection/other 2 7 4 17 6
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Table 3, Response to Induction Treatment by Treatment Arm
Treatment Arm
Variable
+/- —/+ +/+
No. % No. % No. % No. %
First course
CR 20 76.9 15 60.0 12 44.4 10 4 1.7
PR 0 0 2 8.0 1 3.7 2 8.3
Resistance 4 15.4 7 28.0 13 48.1 10 41.7
Death 2 7.7 1 4.0 1 3.7 2 8.3
1 or 2 courses
CR 20 76.9 18 72.0 13 48.1 11 45.8
Resistance 4 15.4 6 24.0 13 48.1 n 45.8
Death 2 7.7 1 4.0 1 3,7 2 8.3
Total 26 25 27 24
lowed by the presence of Auer rods (P = .02) and fever, more patients allografted in the +/— arm, but in general
which was marginally important {P — .09), 
After salvage treatment— without GM-CSF -was ad­
ministered to patients with resistant disease, the overall 
CR rate of the group • /+ was still lower, but not signifi­
cantly (P = .11), than that of the group * /—: 66.7% versus 
80.4%. A similar nonsignificant trend (P — ,34) was ob­
served for the comparison +/• versus —/• : 67.3% versus 
77.4%.
EFS and Survival
Table 5 lists treatments given after the completion of 
induction treatment. Of 62 patients who achieved a CR,
12 received standard maintenance and 16 received one
there was a good distribution of postinduction treatments 
among the four arms. Table 5 also indicates that fewer 
relapses have been reported in the control arm (—/—), 
and more in the GM-CSF-containing arms. The highest 
rate of death in first CR has been reported in the +/— arm, 
a finding which is probably due to the highest incidence of 
allografts. The limited number of patients in the treatment 
arms and groups precludes any valid comparison of the 
duration of CR and of disease-free survival.
The EFS time from evaluation of the last induction 
course was significantly shorter (log-rank P = .02) for the 
* /+ group than for the ■ /— group, whereas the difference 
between groups —/ • and -f/ • was not significant (P =
or two cycles of intensive chemotherapy consolidation, ,16) (Fig 2). Using Cox’s model, after adjustment for the
whereas 20 have been transplanted. There were a few presence of Auer rods, which was the only significant
Table 4. Response to Induction Treatment by Treatment Group
Treatment Group
Variable
• / - • /+ -/ • +/ •
No. % No. % No. % No. %
First course
CR 35 68.6 22 43.1 32 60.4 25 51,0
PR 2 3.9 3 5.9 1 1.9 4 8.2
Resistance 11 21.6 23 45.1 17 32.1 17 34.7
Death 3 5.9 3 5.9 3 5.7 3 6.1
P* .015 .41
OR 2.93 1.53
95% Cl 1.29-6.61 0.68-3.46
1 or 2 courses
CR 38 74.5 24 47.1 33 62.3 29 59.2
Resistance 10 19.6 24 47.1 17 32.1 17 34.7
Death 3 5.9 3 5.9 3 5.7 3 6.1
Pm .008 ,86
OR 3.31 1.18
95% Cl 1.43-7.64 0.51-2.70
Total 51 100 51 100 53 100 49 100
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Table 5. Post-CR Treatment and Outcome After Induction Treatment by Treatment Arm
Treatment Arm
Variable
+ /- -/+ + /+■ Total
No. % No. % No. % No. % No. %
Treatment
Toxicity -+ no 1 0 1 2 4
treatment
Standard maintenance 4 4 1 3 12
Intensive consolidation 11 7 5 3 16
Autologous BMT 1 2 4 2 9
Allogeneic BMT 3 5 2 1 11
Outcome
Continued CR 14 70.0 5 27.8 5 38.5 5 45.4 29 46.8
Bone marrow relapse 5 25.0 8 44.4 7 53.8 5 45.4 25 40.3
CNS relapse 0 0.0 5.6 0 0.0 0 0.0 1 1.6
Death in first CR 1 5.0 4 22.2 1 7.7 1 9.1 7 11.3
Total 20 100 18 100 13 100 11 100 62 100
prognostic factor for EFS (P = .015), similar results were 
obtained regarding the treatment groups.
The overall survival rate from randomization was 32% 
at 3 years, with a median estimation of 15 months and a 
median follow-up duration of 34 months. The total num­
bers of deaths in the four arms were 10, 17, 19, and 17, 
respectively. A trend for a higher death rate (log-rank P 
- .07) was observed in the ■ /+ group versus * /— group 
(OR - 1.51; 95% Cl, 0.92 to 2.49). For the comparison 
47 ■ group versus — /• group, the difference was smaller 
(log-rank P = .37; OR = 1.26; 95% Cl, 0.76 to 2.07).
Time io Recovery of Neutrophils
The time from start of induction to recovery of a neu­
trophil count greater than 0.5 X 109/L was studied by 
treatment arm and group, for patients who achieved a CR 
after the first induction course. Comparison among the 
four treatment arms showed no significant difference (P 
= .28). However, a trend was observed with a shorter 
duration of neutropenia in the +/+ arm and a longer 
duration in the control arm (Fig 3). In addition, there was 
a nearly significant inverse correlation between treatment 
arm (arm 1 to 4) and duration of neutropenia (log-rank 
test for linear trend, P = .09),
Toxiciîies
The main toxicities observed by treatment arm are 
listed in Table 6, which also provides the number of 
clinically or microbiologically documented infections in 
the four randomized arms. Fluid retention, weight gain, 
and hypotension were mainly observed in the two arms 
with postchemotherapy administration of GM-CSF. On 
the other hand, the number of infections was not reduced, 
and the number of days with fever, antibiotics, and time
spent in the hospital in the three treatment arms were not 
lower than in the control arm. Platelet and RBC transfu­
sions were similar in the four arms (data not shown).
DISCUSSION
The aim of the present trial was to improve the outcome 
of induction treatment and the EFS in AML, by adminis­
tration of GM-CSF, using various schedules. However, 
our results appeared disappointing: none of the combined 
modalities of GM-CSF and chemotherapy was superior 
to the standard DNR/Ara-C regimen. With the present 
dose schedules of GM-CSF, it is unlikely that the CR 
rate in AML could be improved by addition of GM-CSF. 
On the contrary, there are indications that GM-CSF, when 
administered during the postinduction chemotherapy pe­
riod, could increase the risk of resistance to induction 
chemotherapy. Unfortunately, this conclusion is based on 
a limited number of patients, since the trial had to be 
stopped prematurely. Confirmatory studies would be use­
ful, but administration of GM-CSF after chemotherapy 
courses to patients with residual leukemic cells should be 
discouraged. However, this precaution might reduce the 
chance of confirmation of our negative results.
The control arm contained, to a certain extent, more 
favorable prognos tic factors in comparison with the other 
randomized treatment arms. Random bias may occur in 
limited series, but with such central randomization, sys­
tematic biases are avoided and the validity of statistical 
tests guaranteed. A posteriori stratification by important 
prognostic factors has been performed to adjust for possi­
ble imbalances of known factors between the treatment 
groups, without changing the initial conclusion.
Statistical analysis was performed on the basis of the 
intention-to-treat principle. In several patients random-
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ized to the +/— and +/+ arms, GM-CSF was delayed, 
according to the protocol, because of a high initial WBC 
count. Also, once started, GM-CSF was prematurely 
stopped in 41 of 51 patients randomized to the —/+ or 
+/+ arms, mainly because of increased blast cells or early 
PMN recovery. In addition, four patients did not receive 
the growth factor at all, because of persisting significant 
levels of circulating blast cells or symptoms related to
leukostasis. Despite these precautionary measures, the CR 
rate was significantly lower when GM-CSF was adminis­
tered during the postinduction period, and this difference 
remained highly significant after adjustment for initial 
WBC count.
All smears were centrally reviewed, especially for re­
sponse. This review, and the subsequent hematologic 
evaluations allowed us to rule out a misinterpretation of
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responses. Such risk of erroneous evaluation had been 
pointed out, with respect to possible cytologic conse­
quences of the administration of HGFs at the bone mar­
row level: an underestimation of the CR rate may result 
from stimulation of early normal progenitor cells that 
could simulate leukemic blast cells, or by a transient stim­
ulation of leukemic cells, which could disappear after 
stopping the growth factor, as reported by Büchner et al.7 
On the other hand, stimulation of mature granulopoiesis 
could dilute the residual leukemic cells and lead to an 
overestimation of the CR rate. In fact, these cytologic 
modifications could mainly lead to confusion between 
CR and PR, but our observation of a lower response rate 
is still found when PR and CR are considered together, 
with a lower total response rate in patients allocated to 
receive GM-CSF during the post induction courses.
It is frequently assumed that the administration of
GM-CSF before induction chemotherapy courses m ight 
stimulate proliferation of leukemic cells and/or induce 
recruitment into the cycle. This biologic effect has been 
observed by cell kinetics methods in some studies2,22,23 
and could enhance leukemic cell kill, Cell kinetic studies 
were not performed in our study. An increase of the W B C  
count cannot be simply attributed to stimulation o f leuke­
mic proliferation* A noticeable increase was observed 
only in five patients, and did not correlate with an unex­
pectedly high CR rate, or, conversely, resistance rate, in  
their study, Ohno et al11 did not observe a greater increase 
of bone marrow blasts in patients who received G-CSF 
2 days before the start of induction chemotherapy than 
in those who received placebo. In fact, the optimum tim ­
ing of administration HGFs for eventual priming of the 
leukemic cells remains largely unknown. The administra­
tion of GM-CSF during several days before the stari o f
Table 6. Main Side Effects, Number of Documented Infections, and Supportive Care by Treatment Arm
Treatment Arm
- / -  (n = 26) + /- (n = 25) - /  + (n = 27) +/-t- (n = 24)
Variable No. % No. % No, % No. %
Bone pain grade 3/4 0 0 0 0 2 7 2  8
Fluid retention ó 23 8 32 11 41 12 5 0
Weight gain (s= 5 kg} 2 8 0 0 4 15 4 1 7
Hypotension 1 4 2 8 ó 22 5
Cardiac 0 0 0 0 2 7 5
Infection 19 73 19 76 22 81 22
Na. of days with fever
Median 5.5 7 7 1 0 . 5
Range 0-63 0-19 0-26 3 -3 0
No. of days of antibiotics
Median 12 18 14 18
Range 0-29 0-37 0-32 0-5Ó
21
21
92
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chemotherapy could induce a hyperleukocytosis, with 
eventual pulmonary infiltrates.23 An early start of GM- 
CSF, 4 to 7 days before induction chemotherapy, might 
explain the relatively low CR rate in patients reported by 
Estey et al,24 when compared with a group of matched 
historical controls. However, these patients also received 
GM-CSF during the postchemotherapy period, which, ac­
cording to the present study, may increase the risk of 
persistent leukemia. An interesting combination of GM- 
CSF with timed-sequential chemotherapy has been pro­
posed by Archimbaud et al.25 In this combination, GM- 
CSF was administered during a short period of 5 days 
between two short courses of chemotherapy to increase 
the recruitment and cell kill of residual leukemic cells.
Our study showed a trend for earlier recovery of PMNs 
in patients who received GM-CSF. A significantly shorter 
duration of neutropenia was observed in most other stud­
ies with GM-CSF13’14’26 or G-CSF.10’15’27 However, in our 
series, as in most others, this slightly accelerated recovery 
did not result in a significant reduction of the rate of 
documented infections or mortality during hypoplasia, or 
of the number of days with fever, duration of administra­
tion of antibiotics, and duration of stay in the hospital. 
Only in the Eastern Cooperative Oncology Group 
(ECOG) study was there a significant decrease of grade 
4 to 5 infections, with a trend for lower therapy-related 
mortality and a higher CR rate. The reasons for this dis­
crepancy with the other studies of GM-CSF12,14,16 remain 
to be explored, taking into account the slightly higher 
daily dose (250 /xg/m2 v 5 (ig/kg) and the use of a yeast- 
derived growth factor. Also in this study, Rowe et al13 
did not observe an increased rate of early relapse in pa­
tients who received GM-CSF during induction and con-
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solidation; however, the risk of promoting the regrowth 
of leukemic cells was reduced in this protocol, with GM- 
CSF being started only on day 11 and in patients with 
no residua] blood or bone marrow blast cells.
Another study with positive results in favor of a combina­
tion with growth factor in AML was reported by Dombret 
et al,15 who used G-CSF in elderly AML patients from day 
9 until day 28 or earlier hematopoietic recovery. These 
investigators observed a significantly higher CR rate in pa­
tients who received the growth factor, without reduction of 
the mortality rate from infection. The higher CR rate was 
related to less resistance of leukemia, especially in patients 
with adverse prognostic factors. This result led to the hy­
pothesis of an antileukemic effect of G-CSF by stimulation 
of terminal differentiation of residual leukemic cells. If con­
firmed, our results might indicate a different, adverse effect 
of GM-CSF. The combination of GM-CSF with antileuke­
mic cytotoxic drugs might have other disadvantages over 
G-CSF with regard to intracellular metabolism of Ara-C: 
the in vivo formation of cytarabine triphosphate (Ara-CTP) 
is decreased by GM-CSF,28 and there is a decreased sensitiv­
ity to Ara-C of leukemic clonogenic cells after exposure to 
this growth factor 4 despite the observed increases in labeling 
index and of numbers of nucleoside transporters.22
Further randomized studies to compare the various 
HGFs at different dose schedules are warranted. Our re­
sults indicate that outside such controlled prospective 
studies, the use of HGF should be avoided in AML, at 
least during the induction period, thus supporting the re­
cent recommendations of an expert panel.29
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